[go: up one dir, main page]

PE20232045A1 - Polipeptidos de interleucina-2 mutante dependientes del ph - Google Patents

Polipeptidos de interleucina-2 mutante dependientes del ph

Info

Publication number
PE20232045A1
PE20232045A1 PE2023001616A PE2023001616A PE20232045A1 PE 20232045 A1 PE20232045 A1 PE 20232045A1 PE 2023001616 A PE2023001616 A PE 2023001616A PE 2023001616 A PE2023001616 A PE 2023001616A PE 20232045 A1 PE20232045 A1 PE 20232045A1
Authority
PE
Peru
Prior art keywords
polypeptides
dependent mutant
immunoconjugates
dependent
mutant interleukin
Prior art date
Application number
PE2023001616A
Other languages
English (en)
Inventor
Lorenzo Dehò
Christian Gassner
Sylvia Herter
Thomas Hofer
Ralf Hosse
Adrian Hugenmattter
Christian Klein
Florian Limani
Ekkehard Moessner
Melanie Obba
Bianca Scherer
Pablo Umana
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20232045A1 publication Critical patent/PE20232045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere en general a polipeptidos de interleucina-2 mutante dependientes del pH que exhiben una union reducida al receptor de IL-2 a pH neutro y retienen la union al receptor de IL-2 a pH reducido. Ademas, la invencion se refiere a inmunoconjugados que comprenden dichos polipeptidos de IL-2 mutante dependientes del pH, moleculas de polinucleotidos que codifican los polipeptidos de IL-2 mutante dependientes del pH o inmunoconjugados, y vectores y celulas huesped que comprenden tales moleculas de polinucleotidos. La invencion se refiere ademas a metodos para producir los polipeptidos de IL-2 mutante dependientes del pH o inmunoconjugados, composiciones farmaceuticas que los comprenden y usos de estos.
PE2023001616A 2020-12-04 2021-12-02 Polipeptidos de interleucina-2 mutante dependientes del ph PE20232045A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20211731 2020-12-04
PCT/EP2021/083864 WO2022117692A2 (en) 2020-12-04 2021-12-02 Ph-dependent mutant interleukin-2 polypeptides

Publications (1)

Publication Number Publication Date
PE20232045A1 true PE20232045A1 (es) 2023-12-27

Family

ID=73726565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001616A PE20232045A1 (es) 2020-12-04 2021-12-02 Polipeptidos de interleucina-2 mutante dependientes del ph

Country Status (15)

Country Link
US (1) US20240092853A1 (es)
EP (1) EP4255923A2 (es)
JP (1) JP2023551563A (es)
KR (1) KR20230117122A (es)
CN (1) CN116635403A (es)
AR (2) AR124246A1 (es)
AU (1) AU2021393752A1 (es)
CA (1) CA3197740A1 (es)
CO (1) CO2023007108A2 (es)
CR (1) CR20230219A (es)
IL (1) IL303381A (es)
MX (1) MX2023006480A (es)
PE (1) PE20232045A1 (es)
TW (1) TW202237632A (es)
WO (1) WO2022117692A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2002355955A1 (en) 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
CN101437847A (zh) 2006-05-08 2009-05-20 菲洛根有限公司 治疗用靶向细胞因子的抗体
WO2008034473A1 (de) 2006-09-20 2008-03-27 Dge Dr.-Ing. Günther Engineering Gmbh Verfahren und vorrichtung zur trennung von methan und kohlendioxid aus biogas
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
NZ719654A (en) * 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
CN117003887A (zh) * 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物

Also Published As

Publication number Publication date
US20240092853A1 (en) 2024-03-21
KR20230117122A (ko) 2023-08-07
JP2023551563A (ja) 2023-12-08
AU2021393752A1 (en) 2023-05-18
CA3197740A1 (en) 2022-06-09
CN116635403A (zh) 2023-08-22
AR124246A1 (es) 2023-03-01
AR129131A2 (es) 2024-07-17
WO2022117692A2 (en) 2022-06-09
EP4255923A2 (en) 2023-10-11
MX2023006480A (es) 2023-06-19
CO2023007108A2 (es) 2023-06-30
IL303381A (en) 2023-08-01
WO2022117692A3 (en) 2022-10-20
CR20230219A (es) 2023-07-07
TW202237632A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
CO2023007108A2 (es) Polipéptidos de interleucina-2 mutante dependientes del ph
PE20191494A1 (es) Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
AR119338A1 (es) Inmunoconjugados que comprenden un polipéptido interleuquina-2 (il-2) mutante y un anticuerpo que se une a cd8
ECSP13012815A (es) Polipéptidos interleuquina- 2 mutantes
MX2022012541A (es) Inmunoconjugados.
CL2020003031A1 (es) Agentes aglutinantes del psma y usos de estos.
CO2022002630A2 (es) Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos
ECSP22016567A (es) Compuestos inhibidores de rip1 y m?todos para prepararlos y usarlos
MX2021015761A (es) Polipeptidos.
AR114445A1 (es) Conjugados de il-15, y sus usos
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
MX2017012679A (es) Polipeptidos que contienen dominios de union de novo y usos de los mismos.
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MX2024003535A (es) Proteina mutante de interleucina-2 y fusion de la misma.
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
MX2016015235A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
AR120886A1 (es) Anticuerpos anti-fgfr2b
PE20221760A1 (es) Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2024001066A1 (es) Nuevos inmunoconjugados de interleucina-7
MX2020004220A (es) Anticuerpos anti-glico-muc1 y sus usos.
MX2022000055A (es) Enzimas de polimerización para reacciones de secuenciación.
CO2020000231A2 (es) Composiciones inmunogénicas que comprenden cea muc1 y tert